Opioid addiction, also known as opioid use disorder (OUD), is a medical condition requiring medical treatment. Together with counseling and support, Braeburn’s next generation medicines are developed with an aim to support patients with OUD as they focus on the reintegration of their lives and communities.
1HHS.gov, Oct 2019, Opioid epidemic by Numbers, Accessed 02/27/2020 https://www.hhs.gov/opioids/about-the-epidemic/index.html
FluidCrystal®* Injection Depot Technology, a next generation proprietary delivery system, includes a lipid-based liquid with a dissolved active ingredient. Upon injection and contact with fluids in the tissue, the lipid solution transforms into a liquid crystalline gel, which encapsulates the active ingredient, allowing for a slow release of the medication over time.
*FluidCrystal® trademark is owned by Camurus and used by Braeburn under license.
Everything we think, say and do is with our patients in mind.
We develop next generation therapies for opioid use disorder treatment.
We are proud to be part of the solution.
Braeburn strives to foster high performing teams that are passionate about being on the front lines of addressing the opioid crisis. We work smarter by leveraging technology and fostering a collaborative environment that encourages individuals to share their talents and voices to bring ideas to life.